Aminoanilide-Based Class I HDAC PROTACs Reveal Distinct Requirements for HDAC Inhibition and Targeted Protein Degradation: Discovery of a Mixed Class I HDAC Inhibitor/Degrader with Selective Anticancer Activity
作者
Stephan Lepper,Lukas Biermann,Emma C. Martens,Irina Honin,Alexandra Hamacher,Linda Schäker‐Hübner,Matthias Ulrich Kassack,Finn Kristian Hansen
出处
期刊:日期:2026-08-17
标识
DOI:10.26434/chemrxiv.15007556/v1
摘要
Histone deacetylases (HDACs) are promising epigenetic targets for cancer therapy. Besides conventional inhibition, targeted protein degradation has emerged as an attractive strategy to achieve selective modulation of HDAC function. Here, we report the design, synthesis, and biological characterization of two series of aminoanilide-based PROTACs targeting class I HDACs. The first series (1a-e) incorporated a classical 2-aminoanilide zinc-binding group, whereas the second series (2a-g) featured a pyridinyl foot-pocket targeting unit to bias selectivity toward HDAC1/2. As anticipated, the latter series displayed potent HDAC1/2 inhibition. However, this modification abolished efficient class I HDAC degradation and was accompanied by a complete loss of cytotoxic activity. In contrast, compound 1c, containing a cereblon ligand and a C8 alkyl linker, emerged as the lead compound. 1c selectively inhibited HDAC1-3, showed intracellular target engagement, and induced partial degradation of HDAC2 and HDAC3 in kinetic degradation assays. Remarkably, 1c exhibited potent antiproliferative activity in cancer cells while displaying 4- to 50-fold lower toxicity toward non-malignant cells, distinguishing it from established class I HDAC inhibitors and degraders. Furthermore, 1c efficiently restored cisplatin sensitivity in the resistant head and neck cancer cell line Cal27CisR through synergistic interactions with cisplatin. Combination treatment enhanced histone H3 acetylation, p21 induction, DNA damage, caspase activation, and apoptotic cell death. Collectively, these findings identify 1c as a mixed class I HDAC inhibitor/degrader with selective anticancer activity and demonstrate that optimization of HDAC inhibitory potency does not necessarily translate into productive targeted protein degradation.